Lynch syndrome, endometrial cancer, and fertility-sparing treatment

Giorgio Bogani,Antonino Ditto,Francesco Raspagliesi

DOI: https://doi.org/10.21037/gpm-2020-02

2020-09-01

Gynecology and Pelvic Medicine

Abstract:Lynch syndrome, endometrial cancer, and fertility-sparing treatment

What problem does this paper attempt to address?

Progression of fertility-sparing treatment for atypical endometrial hyperplasia in a woman with lynch syndrome: a case report and review of the literature

Ya-Ting Hsu,Chi-Hau Chen

DOI: https://doi.org/10.3389/fonc.2024.1422006

2024-08-12

Abstract:Endometrial cancer in Lynch syndrome is characterized by a higher incidence, younger age at onset, and increased recurrence rates compared to sporadic cases, while the safety and efficacy of fertility-sparing treatments remain uncertain. This case report presents the oncology outcome of fertility-preserving treatment in a 39-year-old woman diagnosed with Lynch syndrome and atypical endometrial hyperplasia. Initially, she responded favorably to fertility-preserving treatment but subsequently experienced disease relapse and rapid progression during retreatment. Final pathology revealed endometrial cancer with metastasis to the right ovary, categorized as FIGO 2023 stage IIIA1. This population's unique molecular mechanisms and genetic mutations warrant special consideration when opting for fertility-sparing treatment. We have reviewed and summarized the oncology and pregnancy outcomes among Lynch syndrome and MMR-deficient patients through previous literature. However, no studies have investigated retreatment after recurrence in Lynch syndrome. Our case highlights the potential risks associated with retreatment following relapse. Vigilant monitoring and prompt consideration of surgical intervention are recommended upon disease relapse.
[Lynch syndrome and endometrial cancer]

Anne-Sophie Bats,Léa Rossi,Marie-Aude Le Frere-Belda,Céline Narjoz,Caroline Cournou,Marie Gosset,Charlotte Ngo,Myriam Delomenie,Claude Nos,Hélène Blons,Pierre Laurent-Puig,Fabrice Lecuru

DOI: https://doi.org/10.1016/j.bulcan.2017.06.018

Abstract:Lynch syndrome is a hereditary predisposition to many tumors, in the forefront of which endometrial cancer in women. It is related to the mutation of a mismatch repair gene, involved in DNA mismatch repair. This mutation leads to a loss of expression of the corresponding protein, and to genome instability in tumor cells. Cumulative risk at the age of 70 years is over 40 %. Endometrial cancers related to Lynch syndrome are most of the time sentinel (They reveal the predisposition in half of families.) and are characterized by young age at onset (before 60 years) and low body mass index compared with patients presenting sporadic tumors. Pathological tumor characteristics are debated but it seems to be two types of tumors according to age, older patients having standard tumors and younger ones more aggressive pattern. Endometrial cancers related to Lynch syndrome can be synchronous of ovarian cancer. Therapeutic management does not present any particularity. Conservative treatment can be considered more frequently due to young age of patients but has to respect usual guidelines. Prognosis of these tumors is controversial. Gynaecological screening, although its benefit has not been proved, appears crucial in this population, as well as prophylactic surgery, which remains the best prevention.
Case report: Reproductive organ preservation and subsequent pregnancy for an infertility patient with lynch syndrome-associated synchronous endometrial cancer and colon cancer after treatment with a PD-1 checkpoint inhibitor

Di Cao,Yu Gao,Rong-xin Zhang,Fu-long Wang,Cong Li,Miao-qing Wu,Yi-fan Liu,Dan-dan Li,Gong Chen

DOI: https://doi.org/10.3389/fimmu.2022.1010490

IF: 7.3

2022-10-17

Frontiers in Immunology

Abstract:Currently, immune checkpoint inhibitors (ICIs) are the mainstay of treatment for Lynch syndrome patients. However, the tumor regression features in radiology and pathology are inconsistent for patients who are treated with ICIs, which sometimes confuses surgical decision-making. Here, we report a case in which a 36-year-old patient suffering from infertility was diagnosed with Lynch syndrome-associated synchronous endometrial cancer and colon cancer, and persistently enlarged left iliac paravascular lymph nodes were detected after receiving sintilimab treatment, a programmed cell death 1 (PD-1) receptor inhibitor. Fortunately, when she was about to undergo hysterectomy and bilateral salpingo-oophorectomy, intraoperative pathology examination did not reveal any cancer cells in these lymph nodes, and therefore, her reproductive organs were preserved. Later, the patient successfully conceived and gave birth to a healthy male neonate with no immune-related adverse events (irAEs) during an 11-month follow-up. This case indicates that surgeons should carefully inspect the imaging characteristics after immunotherapy and that organ preservation is possible even for patients who fail to achieve complete clinical regression, which is especially important for female patients of childbearing age.

immunology
Endometrial and Ovarian Cancer in Lynch Syndrome

Marta Ann Crispens,Marta Crispens

DOI: https://doi.org/10.1055/s-0032-1313780

2012-05-30

Clinics in Colon and Rectal Surgery

Abstract:Lynch syndrome (LS) is an autosomal dominant familial cancer risk syndrome that occurs due to a germline mutation in one of several mismatch repair genes and is associated with an increased risk of colorectal, endometrial, and ovarian cancer. The risk of endometrial cancer equals or exceeds that of colorectal cancer in women with LS. The diagnosis of gynecologic cancer precedes that of colorectal cancer in over half of women with metachronous gynecologic and colon cancers, making gynecologic cancer a "sentinel cancer" for LS. There are no studies addressing the effectiveness or safety of chemoprevention for women with LS. Surveillance with gynecologic examination including assessment of symptoms, transvaginal pelvic ultrasonography, endometrial biopsy, and CA125 tumor marker assessment can be offered, but has not been shown to improve outcomes for these patients. Prophylactic hysterectomy with bilateral salpingo-oophorectomy performed after the completion of childbearing may be offered for gynecologic cancer prevention.

gastroenterology & hepatology,surgery
Progress on the diagnosis, treatment, and family management of Lynch syndrome

ZHONG Chenhan,LI Xiaofen,XU Dong,YUAN Ying

DOI: https://doi.org/10.3969/j.issn.1000-8179.2016.20.750

2016-01-01

Abstract:Lynch syndrome is the most common type of genetically determined colon-cancer predisposition syndrome, accounting for 5%of all colorectal cancer (CRC) cases. This hereditary syndrome is characterized by the germline mutation of human mismatch repair genes and microsatellite instability. Recent studies have shown that Lynch syndrome and sporadic CRC differ in diagnosis and treat-ment;these results are especially relevant for the clinical management of Lynch syndrome. In this review, we reverted to the original characterization of Lynch syndrome, and the developments in its screening and diagnosis were summarized. Furthermore, the manage-ment of families with this disorder was discussed.
Endometrial cancer in Lynch syndrome

Shuangshuang Zhao,Lingli Chen,Yuqin Zang,Wenlu Liu,Shiqi Liu,Fei Teng,Fengxia Xue,Yingmei Wang

DOI: https://doi.org/10.1002/ijc.33763

2021-09-09

International Journal of Cancer

Abstract:Lynch syndrome (LS) is an autosomal dominant inherited disease caused by germline pathogenic variants (PVs) in mismatch repair (MMR) genes. LS-associated endometrial cancer (LS-EC) is the most common extraintestinal sentinel cancer caused by germline PVs in MMR genes, including MLH1, MSH2, MSH6, and PMS2. The clinicopathologic features of LS-EC include early age of onset, lower body mass index (BMI), endometrioid carcinoma, and lower uterine segment involvement. There has been significant progress in screening, diagnosis, surveillance, prevention, and treatment of LS-EC. Many studies support universal screening for LS among patients with EC. Screening mainly involves a combination of traditional clinical criteria and molecular techniques, including MMR-immunohistochemistry (MMR-IHC), microsatellite instability (MSI) testing, MLH1 promoter methylation testing and gene sequencing. The effectiveness of endometrial biopsy and transvaginal ultrasound (TVS) for clinical monitoring of asymptomatic women with LS are uncertain yet. Preventive strategies include hysterectomy and bilateral salpingo-oophorectomy (BSO) as well as chemoprophylaxis using exogenous progestin or aspirin. Recent research has revealed the benefits of immunotherapy for LS-EC. The NCCN guidelines recommend pembrolizumab and nivolumab for treating patients with advanced or recurrent microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) EC.This article is protected by copyright. All rights reserved.
Perception about benefits and risks related to combined hormonal contraceptives use in women with Lynch syndrome

Fabio Barra Umberto Perrone Simone Ferrero Stefano Bogliolo Silvia Ottonello Claudio Gustavino Angela Iasci Giovanni Grandi Alessandra Pulliero Maria Grazia Centurioni Alberto Izzotti a Unit of Obstetrics and Gynecology,P.O. 'Ospedale del Tigullio' – ASL4,Chiavari,GE,Italyb Department of Health Sciences (DISSAL),University of Genoa,Genoa,Italyc Department of Neurosciences,Rehabilitation,Ophthalmology,Genetics,Maternal and Child Health (DiNOGMI),University of Genoa,Genoa,Italyd Academic Unit of Obstetrics and Gynecology,IRCCS Ospedale Policlinico San Martino,Genoa,Italye Unit of Obstetrics and Gynecology,IRCCS Ospedale Policlinico San Martino,Genoa,Italyf Department of Medical and Surgical Sciences for Mother,Child and Adult,University of Modena and Reggio Emilia,Azienda Ospedaliero-Universitaria di Modena,Modena,Italyg Unit of Mutagenesis and Cancer Prevention,IRCCS Ospedale Policlinico San Martino,Genoa,Italyh Department of Experimental Medicine (DIMES),University of Genoa,Genoa,Italy

DOI: https://doi.org/10.1080/07853890.2024.2370568

IF: 5.348

2024-06-26

Annals of Medicine

Abstract:Objective Lynch syndrome (LS) is a hereditary condition associated with an increased risk of colorectal and endometrial cancer. This study aimed to assess the knowledge, attitudes, and beliefs of women with LS regarding combined hormonal contraceptive (CHC) use compared to a control group of healthy women.

medicine, general & internal
Lynch Syndrome: From Multidisciplinary Management to Precision Prevention

Arianna Dal Buono,Alberto Puccini,Gianluca Franchellucci,Marco Airoldi,Michela Bartolini,Paolo Bianchi,Armando Santoro,Alessandro Repici,Cesare Hassan

DOI: https://doi.org/10.3390/cancers16050849

2024-02-21

Cancers

Abstract:Background and Aims: Lynch syndrome (LS) is currently one of the most prevalent hereditary cancer conditions, accounting for 3% of all colorectal cancers and for up to 15% of those with DNA mismatch repair (MMR) deficiency, and it was one of the first historically identified. The understanding of the molecular carcinogenesis of LS tumors has progressed significantly in recent years. We aim to review the most recent advances in LS research and explore genotype-based approaches in surveillance, personalized cancer prevention, and treatment strategies. Methods: PubMed was searched to identify relevant studies, conducted up to December 2023, investigating molecular carcinogenesis in LS, surveillance strategies, cancer prevention, and treatment in LS tumors. Results: Multigene panel sequencing is becoming the benchmark in the diagnosis of LS, allowing for the detection of a pathogenic constitutional variant in one of the MMR genes. Emerging data from randomized controlled trials suggest possible preventive roles of resistant starch and/or aspirin in LS. Vaccination with immunogenic frameshift peptides appears to be a promising approach for both the treatment and prevention of LS-associated cancers, as evidenced by pre-clinical and preliminary phase 1/2a studies. Conclusions: Although robust diagnostic algorithms, including prompt testing of tumor tissue for MMR defects and referral for genetic counselling, currently exist for suspected LS in CRC patients, the indications for LS screening in cancer-free individuals still need to be refined and standardized. Investigation into additional genetic and non-genetic factors that may explain residual rates of interval cancers, even in properly screened populations, would allow for more tailored preventive strategies.

oncology
Lynch Syndrome: From Carcinogenesis to Prevention Interventions

Donatella Gambini,Stefano Ferrero,Elisabetta Kuhn

DOI: https://doi.org/10.3390/cancers14174102

2022-08-24

Abstract:Lynch syndrome (LS) is the most common inherited disorder responsible for an increased risk of developing cancers at different sites, most frequently in the gastrointestinal and genitourinary tracts, caused by a germline pathogenic variant affecting the DNA mismatch repair system. Surveillance and risk-reducing procedures are currently available and warranted for LS patients, depending on underlying germline mutation, and are focused on relevant targets for early cancer diagnosis or primary prevention. Although pharmacological approaches for preventing LS-associated cancer development were started many years ago, to date, aspirin remains the most studied drug intervention and the only one suggested by the main surveillance guidelines, despite the conflicting findings. Furthermore, we also note that remarkable advances in anticancer drug discovery have given a significant boost to the application of novel immunological strategies such as immunocheckpoint inhibitors and vaccines, not only for cancer treatment, but also in a preventive setting. In this review, we outline the clinical, biologic, genetic, and morphological features of LS as well as the recent three-pathways carcinogenesis model. Furthermore, we provide an update on the dedicated screening, surveillance, and risk-reducing strategies for LS patients and describe emerging opportunities of harnessing the immune system.
Lynch syndrome for the gynaecologist

Neil AJ Ryan,Raymond FT McMahon,Neal C Ramchander,Mourad W Seif,D Gareth Evans,Emma J Crosbie

DOI: https://doi.org/10.1111/tog.12706

2021-01-01

Abstract:KEY CONTENT: Lynch syndrome is an autosomal dominant condition closely associated with colorectal, endometrial and ovarian cancer.Women with Lynch syndrome are at increased risk of both endometrial and ovarian cancer and should be offered personalised counselling regarding family planning, red flag symptoms and risk-reducing strategies.Surveillance for gynaecological cancer in women with Lynch syndrome remains controversial; more robust data are needed to determine its effectiveness.Universal testing for Lynch syndrome in endometrial cancer is being adopted by centres across Europe and is now recommended by the National Institute for Health and Care Excellence; thus, gynaecologists must become familiar with testing strategies and their results.Testing strategies involve risk stratification of cancers based on phenotypical features and definitive germline testing.LEARNING OBJECTIVES: To define the pathogenesis of Lynch syndrome and its associated gynaecological cancers.To understand the testing strategies for Lynch syndrome in women with gynaecological cancer.To learn how best to counsel women with Lynch syndrome regarding gynaecological cancer and risk-reducing strategies to enable informed decision-making.ETHICAL ISSUES: Offering gynaecological surveillance despite a lack of robust evidence for its clinical effectiveness may falsely reassure women and delay risk-reducing hysterectomy.Genetic testing may yield variants of unknown significance with ill-defined clinical implications, which can lead to confusion and anxiety.Genetic testing has implications not only for the individual, but also for the whole family, so expert counselling is crucial.
Surgical management of a congenital genital tract abnormality in a patient with Lynch syndrome

Eniola Olayato-Aribo,Nicholas Wood,Divya Nagaiah,Thomas Underwood

DOI: https://doi.org/10.1136/bcr-2022-249833

2022-12-02

Abstract:Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer, is an inherited cancer syndrome which increases the risk of developing colorectal cancer and endometrial cancer. Individuals with LS have an increased risk of cancers of the ovary, urinary tract, stomach, small intestine, pancreas, biliary tract, brain and skin. Cancer risk reduction is recommended through chemoprevention (aspirin), surveillance (colonoscopy, assessment of the endometrium and ovaries via USS, aspiration biopsy and tumour marker monitoring; CA125) or risk reduction surgery, that is, total hysterectomy and bilateral salpingo-oophorectomy.This is a case of a nulliparous woman in her early 30s with LS and a congenital genital tract malformation. She had a unicornuate (left) uterus and a vestigial (right) uterine horn. There was an inability to obtain a conclusive set of endometrial biopsies in this patient due to the nature of the patient's congenital uterine abnormality. In this case, surgery was recommended to excise the vestigial horn and fallopian tube in order to optimise surveillance and fertility.
Lynch Syndrome: Report of One Case and Literature Review

Yanping GUO,Chunbao WANG,Yang LI,Xiaofeng YANG

DOI: https://doi.org/10.3881/j.issn.1000-503X.2018.03.024

2018-01-01

Abstract:This article reports a female type Ⅱ Lynch syndrome patient who suffered from colon cancer and endometrium carcinoma consecutively. We also briefly elucidate the pathogenesis,clinicopathological features,screening,and management of Lynch syndrome. Regular screening and early diagnosis and treatment may help to reduce the incidences and mortality rates of tumors associated with Lynch syndrome.
Research developments of Lynch syndrome related cancers in female patients

Ting Yu,Wanjun Qu,Ying Zhou,Dabao Wu,Weiping Hu

DOI: https://doi.org/10.3969/J.issn.1672－6790.2018.03.036

2018-01-01

Abstract:Lynch syndrome (LS) is an autosomal dominant inherited disease ,which usually presented as multi－system tomorigenesis.The detection rate increased with the fast development of molecular genetic methods ,this allowed more scientific care program for LS related cancers to be performed.As a systematic disease,studies of LS were common－ly confined in clinical department ,which limits complex evaluation and systematic follow－up in LS.In our study,we sum－marize developments in screening ,diagnosis and health care of female LS patients ,to provide assistance in the manage－ment of LS patients and their family and offer some guidence about the therapy for each clinical department .
Clonal origin and genomic diversity in Lynch syndrome‐associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of MLH1 p.L582H

Kotaro Takahashi,Nozomi Yachida,Ryo Tamura,Sosuke Adachi,Shuhei Kondo,Tatsuya Abé,Hajime Umezu,Hiromi Nyuzuki,Shujiro Okuda,Hirofumi Nakaoka,Kosuke Yoshihara

DOI: https://doi.org/10.1002/gcc.23231

2024-03-11

Genes Chromosomes and Cancer

Abstract:Lynch syndrome‐associated endometrial cancer patients often present multiple synchronous tumors and this assessment can affect treatment strategies. We present a case of a 27‐year‐old woman with tumors in the uterine corpus, cervix, and ovaries who was diagnosed with endometrial cancer and exhibited cervical invasion and ovarian metastasis. Her family history suggested Lynch syndrome, and genetic testing identified a variant of uncertain significance, MLH1 p.L582H. We conducted immunohistochemical staining, microsatellite instability analysis, and Sanger sequencing for Lynch syndrome‐associated cancers in three generations of the family and identified consistent MLH1 loss. Whole‐exome sequencing for the corpus, cervical, and ovarian tumors of the proband identified a copy‐neutral loss of heterozygosity (LOH) occurring at the MLH1 position in all tumors. This indicated that the germline variant and the copy‐neutral LOH led to biallelic loss of MLH1 and was the cause of cancer initiation. All tumors shared a portion of somatic mutations with high mutant allele frequencies, suggesting a common clonal origin. There were no mutations shared only between the cervix and ovary samples. The profiles of mutant allele frequencies shared between the corpus and cervix or ovary indicated that two different subclones originating from the corpus independently metastasized to the cervix or ovary. Additionally, all tumors presented unique mutations in endometrial cancer‐associated genes such as ARID1A and PIK3CA. In conclusion, we demonstrated clonal origin and genomic diversity in a Lynch syndrome‐associated endometrial cancer, suggesting the importance of evaluating multiple sites in Lynch syndrome patients with synchronous tumors.

oncology,genetics & heredity
Fertility-sparing treatment in MSI-H/MMRd endometrial carcinoma or atypical endometrial hyperplasia: A systematic review and meta-analysis

Tianyu Zhang,Xinyue Zhang,Peng Peng,Jiaxin Yang

DOI: https://doi.org/10.1016/j.ejogrb.2024.09.006

Abstract:Introduction: This systematic review and meta-analysis aimed to describe the oncological and reproductive outcomes of patients with MSI-H/MMRd endometrial carcinoma (EC) or atypical endometrial hyperplasia (AEH) undergoing fertility-sparing treatment. Methods: The study protocol was registered with the PROSPERO database (No: CRD42024530406). A systematic literature search in major electronic databases (PubMed, Embase, and Cochrane Library) was conducted from January 1, 2013 to August 10, 2024. The primary outcomes were complete remission (CR) rate and recurrence rate. Other outcomes included oncological outcomes in patients with Lynch syndrome and overall patient fertility status. Results: The study included ten retrospective studies summarizing 66 patients with MSI-H/MMRd undergoing fertility-sparing treatment. The publication bias analysis was low. The length of follow-up varied from 3 to 164 months according to the different studies analyzed. After fertility-sparing treatment, 61.8 % of patients achieved CR, and 41.2 % of patients relapsed. Twelve patients were identified with germline mutations in Lynch syndrome, nine (75 %) achieved CR, and seven (77.8 %) relapsed. Only one study with active use of assisted reproductive technology reported a 1-year cumulative pregnancy rate of more than 60 % and more than half live births, while the remaining five studies assessed fertility outcomes and reported only one live birth. Conclusion: EC and AEH patients with the MSI-H/MMRd subtype had a low remission rate and high recurrence rate compared to conservative treatment. Caution is recommended when evaluating fertility-sparing therapy for patients with the MSI-H/MMRd subtype.
Clinicopathological screening of Lynch syndrome：a report of 2 cases and literature review

Jing-wen SI,Li WANG,Xiao-jun BA,Xu ZHANG,Ying DONG,Ji-xin ZHANG,Wen-ting LI,Ting LI

DOI: https://doi.org/10.3969/j.issn.1671-167X.2015.05.025

2015-01-01

Abstract:Lynch syndrome is an autosomal dominant genetic disease characterized by the early onset of colon cancer, endometrial cancer and other tumors caused by a genetic mutation within DNA mismatch repair (MMR) genes.A small subgroup (approximately 3% -5%) of endometrial cancer and colorectal cancer is related to Lynch syndrome .Identification of these patients in clinical practice will be of great benefit to the relatives and patients themselves .We reported two cases, and reviewed the literature and clinical diagnostic guideline.MMR protein was lost in the tumors.Meanwhile the two cases had different clinicopathological characteristics.Together with the literature, our findings may suggest that the MMR protein expression, associated molecular alterations and clinicopathological features and biological behavior of endometrial cancer and colorectal cancer related to Lynch syndrome are different .Thus the algorithm for detection the patients at highest risk is different .To detect the MMR loss by immunohisto-chemistry is a practicalscreening method.
Tumor Testing and Genetic Analysis to Identify Lynch Syndrome Patients in an Italian Colorectal Cancer Cohort

Antonino Pantaleo,Giovanna Forte,Filomena Cariola,Anna Maria Valentini,Candida Fasano,Paola Sanese,Valentina Grossi,Antonia Lucia Buonadonna,Katia De Marco,Martina Lepore Signorile,Anna Filomena Guglielmi,Andrea Manghisi,Gianluigi Gigante,Raffaele Armentano,Vittoria Disciglio,Cristiano Simone

DOI: https://doi.org/10.3390/cancers15205061

2023-10-20

Cancers

Abstract:Lynch syndrome (LS) is an inherited cancer susceptibility syndrome caused by germline mutations in a DNA mismatch repair (MMR) gene or in the EPCAM gene. LS is associated with an increased lifetime risk of colorectal cancer (CRC) and other malignancies. The screening algorithm for LS patient selection is based on the identification of CRC specimens that have MMR loss/high microsatellite instability (MSI-H) and are wild-type for BRAFV600. Here, we sought to clinically and molecularly characterize patients with these features. From 2017 to 2023, 841 CRC patients were evaluated for MSI and BRAFV600E mutation status, 100 of which showed MSI-H. Of these, 70 were wild-type for BRAFV600. Among these 70 patients, 30 were genetically tested for germline variants in hereditary cancer predisposition syndrome genes. This analysis showed that 19 of these 30 patients (63.3%) harbored a germline pathogenic or likely pathogenic variant in MMR genes, 2 (6.7%) harbored a variant of unknown significance (VUS) in MMR genes, 3 (10%) harbored a VUS in other cancer-related genes, and 6 (20%) were negative to genetic testing. These findings highlight the importance of personalized medicine for tailored genetic counseling, management, and surveillance of families with LS and other hereditary cancer syndromes.

oncology
Lynch Syndrome-associated Genomic Variants

Robert Botea,Madalina Piron-Dumitrascu,Tiberiu Augustin Georgescu,Camil Laurentiu Bohiltea,Silviu Cristian Voinea,Valentin Nicolae Varlas,Simona Raluca Iacoban,Nicolae Suciu

DOI: https://doi.org/10.15403/jgld-5856

2024-09-29

Abstract:Background and aims: Lynch Syndrome, a hereditary disorder characterized by germline mutations in mismatch repair (MMR) genes, is a major contributor to colorectal cancers. It has also been identified in endometrial cancer. Despite the established role of MMR deficiency in tumorigenesis, the specific genomic alterations driving Lynch syndrome-associated endometrial cancer, and their overlap with colorectal cancer, remain incompletely understood. This study aims to fill this gap by performing a detailed comparative analysis of germline and somatic mutations in endometrial cancer within the context of Lynch syndrome. Methods: We conducted whole exome sequencing on matched germline and somatic DNA from 13 patients diagnosed with Lynch syndrome-associated endometrial cancer. High-depth sequencing was performed, followed by rigorous bioinformatics analysis to identify and annotate variants, focusing on their potential pathogenicity and relevance to both endometrial and colorectal cancer. Results: Our analysis revealed 1,118 germline and 14,051 somatic variants, with 493 variants common to both. Recurrent pathogenic mutations in MLH1, MSH2, and MSH6 were confirmed, highlighting their critical role in Lynch syndrome. Notably, frequent somatic mutations in the PIK3CA and PTEN genes were identified, implicating the PI3K/AKT/mTOR pathway as a key oncogenic driver in these cancers. Additionally, novel somatic mutations in genes related to the extracellular matrix such as FBN1 and SPARC were uncovered, suggesting a possible unique role in endometrial tumor progression. Conclusions: This study provides new insights into the molecular basis of Lynch syndrome-associated endometrial cancer, emphasizing the overlap in oncogenic pathways with colorectal cancer. The discovery of shared and unique genetic mutations highlights the importance of developing combined treatment strategies and suggests that targeting these specific mutations could improve therapy for patients with Lynch syndrome-associated cancers.
Fertility preservation in lymphoma patients treated with immunochemotherapy regimens with or without radiotherapy: results of a retrospective multicenter Italian study (Ferty care)

Ombretta Annibali,Alessia Castellino,Natalia Cenfra,Mariavita Ciccarone,Francesco Rotondo,Carla Minoia,Luigi Petrucci,Guido Gini,Chiara Rusconi,Valentina Bozzoli,Maura Nicolosi,Gloria Margiotta,Erika Meli,Federica Cocito,Sara Bigliardi,Sabino Ciavarella,Cristiano Tesei,Francesco Zaja

DOI: https://doi.org/10.1080/10428194.2024.2361358

2024-06-08

Leukemia & Lymphoma

Abstract:This is a retrospective, multicentric study, aimed to describe the real-life application of fertility preservation methods during treatment in female lymphoma patients, aged 18–40 years old, diagnosed between Oct 1st/2010 and May 31st/2018. Among 414 women included, median age was 28 years old, histologies were: HL 74%, PMBCL 13%, DLBCL 10%, others 3%. First line treatments were: ABVD in 295 (71%), R-CHOP like in 102 (25%), higher intensity regimens in 17 (4%) cases. Fertility preservation strategies were: GnRHa in 315 (78%), Oral Contraceptive in 41 (10%), oocytes and ovarian tissue cryopreservation in 55 and 42 patients, respectively. After therapy, we observed a restored regular period in 293 (70%) and premature ovarian failure (POF) in 33 (8%), Furthermore we recorded 43 pregnancies, all spontaneous with 5 years median follow-up. Median age at diagnosis and number of lines of treatment correlate with higher rate of amenorrhea, risk of POF and menopause ( p < 0.001).

oncology,hematology
Gut Microbiota Analysis in Postoperative Lynch Syndrome Patients

Giorgia Mori,Beatrice Silvia Orena,Ilenia Cultrera,Giulia Barbieri,Alessandra M. Albertini,Guglielmina Nadia Ranzani,Ileana Carnevali,Maria Grazia Tibiletti,Maria Rosalia Pasca

DOI: https://doi.org/10.3389/fmicb.2019.01746

IF: 5.2

2019-07-30

Frontiers in Microbiology

Abstract:Lynch syndrome (LS) is a dominantly inherited condition with incomplete penetrance, characterized by high predisposition to colorectal cancer (CRC), endometrial and ovarian cancers, as well as to other tumors. LS is associated with constitutive DNA mismatch repair (MMR) gene defects, and carriers of the same pathogenic variants can show great phenotypic heterogeneity in terms of cancer spectrum. In the last years, human gut microbiota got a foothold among risk factors responsible for the onset and evolution of sporadic CRC, but its possible involvement in the modulation of LS patients' phenotype still needs to be investigated. In this pilot study, we performed 16S rRNA gene sequencing of bacterial DNA extracted from fecal samples of 10 postoperative LS female patients who had developed colonic lesions (L-CRC) or gynecological cancers (L-GC). Our preliminary data show no differences between microbial communities of L-CRC and L-GC patients, but they plant the seed of the possible existence of a fecal microbiota pattern associated with LS genetic background, with Faecalibacterium prausnitzii, Parabacteroides distasonis, Ruminococcus bromii, Bacteroides plebeius, Bacteroides fragilis and Bacteroides uniformis species being the most significantly over-represented in LS patients (comprising both L-CRC and L-GC groups) compared to healthy subjects.

microbiology

Lynch syndrome, endometrial cancer, and fertility-sparing treatment

Progression of fertility-sparing treatment for atypical endometrial hyperplasia in a woman with lynch syndrome: a case report and review of the literature

[Lynch syndrome and endometrial cancer]

Case report: Reproductive organ preservation and subsequent pregnancy for an infertility patient with lynch syndrome-associated synchronous endometrial cancer and colon cancer after treatment with a PD-1 checkpoint inhibitor

Endometrial and Ovarian Cancer in Lynch Syndrome

Progress on the diagnosis, treatment, and family management of Lynch syndrome

Endometrial cancer in Lynch syndrome

Perception about benefits and risks related to combined hormonal contraceptives use in women with Lynch syndrome

Lynch Syndrome: From Multidisciplinary Management to Precision Prevention

Lynch Syndrome: From Carcinogenesis to Prevention Interventions

Lynch syndrome for the gynaecologist

Surgical management of a congenital genital tract abnormality in a patient with Lynch syndrome

Lynch Syndrome: Report of One Case and Literature Review

Research developments of Lynch syndrome related cancers in female patients

Clonal origin and genomic diversity in Lynch syndrome‐associated endometrial cancer with multiple synchronous tumors: Identification of the pathogenicity of MLH1 p.L582H

Fertility-sparing treatment in MSI-H/MMRd endometrial carcinoma or atypical endometrial hyperplasia: A systematic review and meta-analysis

Clinicopathological screening of Lynch syndrome：a report of 2 cases and literature review

Tumor Testing and Genetic Analysis to Identify Lynch Syndrome Patients in an Italian Colorectal Cancer Cohort

Lynch Syndrome-associated Genomic Variants

Fertility preservation in lymphoma patients treated with immunochemotherapy regimens with or without radiotherapy: results of a retrospective multicenter Italian study (Ferty care)

Gut Microbiota Analysis in Postoperative Lynch Syndrome Patients